Astellas

Astellas Pharma Inc. Discontinues Development of Darexaban (YM150),an Oral Direct Factor Xa Inhibitor

Tokyo, September 28, 2011 - Astellas Pharma Inc. (Tokyo:4503 “Astellas”) announced that it has decided to discontinue the global development of darexaban maleate (generic name, development code name: YM150, “darexaban”), an oral direct Factor Xa inhibitor for all indications.
 

No votes yet

Astellas Files Lawsuit Against Sandoz For Patent Litigation In Canada

TOKYO (ENP Newswire )- Astellas Pharma Inc. ('Astellas'; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced today that Astellas and its Canadian affiliate Astellas Pharma Canada, Inc. jointly filed a Notice of Application pursuant to the Patented Medicine (Notice of Compliance) Regulations in Canada against Sandoz Canada Inc. ('Sandoz') in response to Sandoz's abbreviated new drug submission ('ANDS') for a generic version of Prograf (generic name: tacrolimus hydrate).

Syndicate content